Bullous Pemphigoid – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Bullous Pemphigoid – Pipeline Review, H2 2016’, provides an overview of the Bullous Pemphigoid pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bullous Pemphigoid, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bullous Pemphigoid

The report reviews pipeline therapeutics for Bullous Pemphigoid by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bullous Pemphigoid therapeutics and enlists all their major and minor projects

The report assesses Bullous Pemphigoid therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bullous Pemphigoid

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bullous Pemphigoid

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bullous Pemphigoid pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

iCo Therapeutics Inc.

Immungenetics AG

True North Therapeutics Inc

TxCell SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Bullous Pemphigoid Overview 6

Therapeutics Development 7

Pipeline Products for Bullous Pemphigoid - Overview 7

Bullous Pemphigoid - Therapeutics under Development by Companies 8

Bullous Pemphigoid - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Bullous Pemphigoid - Products under Development by Companies 11

Bullous Pemphigoid - Companies Involved in Therapeutics Development 12

iCo Therapeutics Inc. 12

Immungenetics AG 13

True North Therapeutics Inc 14

TxCell SA 15

Bullous Pemphigoid - Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 22

Drug Profiles 24

bertilimumab - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

dimethyl fumarate - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

ENTX-BP - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

TNT-009 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Bullous Pemphigoid - Dormant Projects 32

Bullous Pemphigoid - Product Development Milestones 33

Featured News & Press Releases 33

Jun 14, 2016: Immune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States 33

Nov 09, 2015: Immune Pharmaceuticals Announces FDA Acceptance of Investigational New Drug (IND) Application in the U.S. for Bertilimumab for the Treatment of Bullous Pemphigoid 34

Oct 07, 2015: Immune Pharmaceuticals Submits Investigational New Drug Application in the U.S. for its Lead Product Candidate Bertilimumab for the Treatment of Bullous Pemphigoid 34

Jul 13, 2015: Immune Pharmaceuticals to present bertilimumab at The International Eosinophil Society workshop on Personalized Medicine 35

Jun 25, 2015: Immune Pharmaceuticals Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid 35

Mar 31, 2015: Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 36

Feb 05, 2015: Immune Pharmaceuticals To Present At The BIO CEO & Investor Conference 37

Dec 09, 2014: CEO Dr. Daniel Teper of Immune Pharmaceuticals to Be Interviewed Live on Clear Channel - iHeart Business Talk Radio - December 9, 2014 37

Jul 30, 2014: Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 37

Appendix 38

Methodology 38

Coverage 38

Secondary Research 38

Primary Research 38

Expert Panel Validation 38

Contact Us 38

Disclaimer 39

List of Tables

List of Tables

Number of Products under Development for Bullous Pemphigoid, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Bullous Pemphigoid – Pipeline by iCo Therapeutics Inc., H2 2016 12

Bullous Pemphigoid – Pipeline by Immungenetics AG, H2 2016 13

Bullous Pemphigoid – Pipeline by True North Therapeutics Inc, H2 2016 14

Bullous Pemphigoid – Pipeline by TxCell SA, H2 2016 15

Assessment by Monotherapy Products, H2 2016 16

Number of Products by Stage and Target, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Bullous Pemphigoid – Dormant Projects, H2 2016 32

List of Figures

List of Figures

Number of Products under Development for Bullous Pemphigoid, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 16

Number of Products by Targets, H2 2016 17

Number of Products by Stage and Targets, H2 2016 17

Number of Products by Mechanism of Actions, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Types, H2 2016 22

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports